NCT07454720

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab Combined With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Resectable Rectal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 165 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer

Conditions

• Locally Advanced Resectable Rectal Cancer

Interventions

Type	Name	Description
DRUG	Adebrelimab in combination with SHR-8068 and chemotherapy	Adebrelimab in combination with SHR-8068 and chemotherapy
DRUG	Adebrelimab combined with chemotherapy	Adebrelimab combined with chemotherapy
DRUG	chemotherapy	chemotherapy

Timeline

• Start date: 2026-03-01
• Primary completion: 2032-11-01
• Completion: 2035-11-01
• First posted: 2026-03-06
• Last updated: 2026-03-06

Locations

1 site across 1 country: China